For the quarter and year ended March 31, 2025
Awaiting price reaction for this filing.
Sarda Proteins has submitted its Integrated Filing (Financials) for Q4 and FY25 to BSE under the SEBI-mandated unified filing format. The Board approved the Standalone Audited Financial Results along with the Audit Report for the period. The company has reported zero financial indebtedness — no outstanding loans, cash credit facilities, unlisted debt securities, or NCDs as on date. There are no defaults on any loans or debt instruments, and no related party transactions were disclosed for the half-year period. The audit report carries no modified opinion, meaning there are no qualifications, emphasis of matter, or adverse remarks from the auditors. No funds were raised through public issue, rights issue, preferential issue, or QIP during the period.
This is largely a routine regulatory compliance filing with no negative disclosures — zero debt, no defaults, clean audit, and no related party concerns. For shareholders, it signals financial stability and a clean balance sheet, though the absence of detailed revenue/profit figures in this filing means it is unlikely to move the stock on its own.